Thomas Andrew Davis's Net Worth
$30.3 Thousand
Who is Thomas Andrew Davis?
Thomas Andrew Davis does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Celldex Therapeutics, Inc., GENOCEA BIOSCIENCES, INC., and GENVEC INC.
SEC CIK
Thomas Andrew Davis's CIK is 0001338185
Past Insider Trading and Trends
2020 was Thomas Andrew Davis's most active year for acquiring shares with 4 total transactions. Thomas Andrew Davis's most active month to acquire stocks was the month of May. 2022 was Thomas Andrew Davis's most active year for disposing of shares, totalling 2 transactions. Thomas Andrew Davis's most active month to dispose stocks was the month of February. 2009 saw Thomas Andrew Davis paying a total of $650,928.00 for 82,268 shares, this is the most they've acquired in one year. In 2022 Thomas Andrew Davis cashed out on 3,808 shares for a total of $4,352.45, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Celldex Therapeutics, Inc. (CLDX) Snapshot price: $44
Executive VP & CMOThomas Andrew Davis owns 1,011 units of Common Stock which is worth $44,484.00. In the year 2008 Thomas Andrew Davis acquired a total of 8,368 shares in Celldex Therapeutics, Inc. at a cost of $9,435.11.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 5
| |||
Form 4
|
∞
| 2.5K |
$3.78 | $9,435.11 | 2.5K |
Sep 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 21
| |||
Form 4
|
∞
| 5.87K |
—
|
—
| 5.87K |
Jan 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
GENOCEA BIOSCIENCES, INC. No price found
CHIEF MEDICAL OFFICERThomas Andrew Davis owns 68,330 units of Common Stock. In the year 2018 Thomas Andrew Davis filed a total of 8 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -1.57% | -1.09K |
$1.25 | -$1,363.75 | 68.33K |
Apr 4
| |||
Form 4
| +69.78% | 28.53K |
$1.10 | -$2,988.70 | 69.42K |
Mar 15 - Mar 16
| |||
Form 4
|
∞
| 31.25K |
—
|
—
| 31.25K |
Mar 15
| |||
Form 4
|
∞
| 6.62K |
—
|
—
| 6.62K |
Jun 1
| |||
Form 4
|
∞
| 12.3K |
—
|
—
| 12.3K |
Apr 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
GENVEC INC No price found
Chief Medical OfficerThomas Andrew Davis owns 5,000 units of Common Stock. In the year 2005 Thomas Andrew Davis acquired a total of 5,000 shares in GENVEC INC at a cost of $9,100.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 18
| |||
Form 4
|
∞
| 5K |
$1.82 | $9,100.00 | 5K |
Nov 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||